Please login to the form below
citalopram
This page shows the latest citalopram news and features for those working in and with pharma, biotech and healthcare.
Lundbeck challenge to EC pay-for-delay ruling fails
market in order to keep the price of Celexa (citalopram) artificially high.
Latest news
-
Lundbeck CEO resigns after rule breach
Compounding this has been a legal battle with the European Commission, which ruled that Lundbeck collaborated with several other companies to delay the entry of generic competition for Celexa/ Cipramil (citalopram).
-
EC fines J&J and Novartis in pay-for-delay case
Cipramil (citalopram), although the company has rejected the accusations and appealed the decision.
-
Pipeline: Major depressive disorder therapeutics
A combination of low-dose pipamperone (a dopamine D4 and serotonin 2A receptor antagonist) and citalopram (an SSRI and dopamine D2 receptor antagonist) is in phase III development with PharmaNeuroBoost. ... Pipamperone has been shown to accelerate the
-
Lundbeck presses on with cost-saving programme
its big-selling antidepressant Celexa/ Cipramil (citalopram).
-
Lundbeck still 'appalled' by EC's €94m anti-competition fine
An EC investigation concluded in June the Danish pharma company had collaborated with several other companies to delay the entry of generic competition for its big-selling antidepressant Celexa/ Cipramil (citalopram).
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s RSV vaccine approved by FDA for older adults
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Tuberculosis – why it remains a major global public health challenge
- Whitepaper: Closing the gap with compelling healthcare communications
No results were found
PMHub
Springer Nature
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...
Latest intelligence
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
